Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

[1]  S. Madhi,et al.  Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials , 2023, The Lancet. Child & adolescent health.

[2]  L. Citrome,et al.  Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update , 2022, Annals of Internal Medicine.

[3]  S. Madhi,et al.  Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis , 2022, The Lancet.

[4]  S. Madhi,et al.  Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. , 2022, The New England journal of medicine.

[5]  C. E. Escobar Liquitay,et al.  Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. , 2021, The Cochrane database of systematic reviews.

[6]  L. Mollema,et al.  Antibody Responses to Respiratory Syncytial Virus: A Cross-Sectional Serosurveillance Study in the Dutch Population Focusing on Infants Younger Than 2 Years , 2020, The Journal of infectious diseases.

[7]  S. Madhi,et al.  Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. , 2020, The New England journal of medicine.

[8]  B. Graham,et al.  Development and Standardization of a High-Throughput Multiplex Immunoassay for the Simultaneous Quantification of Specific Antibodies to Five Respiratory Syncytial Virus Proteins , 2019, mSphere.

[9]  M. Levine,et al.  Epidemiology, Risk Factors, and Outcomes of Respiratory Syncytial Virus Infections in Newborns in Bamako, Mali , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  O. Engelhardt,et al.  Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study , 2018, Vaccine.

[11]  M. P. Griffin,et al.  Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants , 2018, The Pediatric infectious disease journal.

[12]  M. Esser,et al.  Development of a High-Throughput Respiratory Syncytial Virus Fluorescent Focus-Based Microneutralization Assay , 2017, Clinical and Vaccine Immunology.

[13]  D. Nokes,et al.  Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya , 2017, PloS one.

[14]  N. Patel,et al.  A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants , 2017, Science Translational Medicine.

[15]  M. P. Griffin,et al.  Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults , 2016, Antimicrobial Agents and Chemotherapy.

[16]  E. Walsh,et al.  Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus , 2016, PloS one.

[17]  C. Palomo,et al.  Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses , 2016, Journal of Virology.

[18]  G. Chuang,et al.  Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera , 2015, Science Translational Medicine.

[19]  B. Graham,et al.  Novel antigens for RSV vaccines. , 2015, Current opinion in immunology.

[20]  J. Scott,et al.  Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya , 2015, Vaccine.

[21]  E. Walsh,et al.  Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. , 2014, The Journal of infectious diseases.

[22]  A. Falsey,et al.  Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness , 2014, The Journal of infectious diseases.

[23]  S. Kumari,et al.  Development of a Luciferase Immunoprecipitation System Assay To Detect IgG Antibodies against Human Respiratory Syncytial Virus Nucleoprotein , 2014, Clinical and Vaccine Immunology.

[24]  U. Baxa,et al.  Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.

[25]  C. Palomo,et al.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention , 2012, Proceedings of the National Academy of Sciences.

[26]  C. Vela,et al.  Serum antibody response to respiratory syncytial virus F and N proteins in two populations at high risk of infection: children and elderly. , 2010, Journal of virological methods.

[27]  P. Cane,et al.  The Level and Duration of RSV-Specific Maternal IgG in Infants in Kilifi Kenya , 2009, PloS one.

[28]  D. Bhella,et al.  The 24-Angstrom Structure of Respiratory Syncytial Virus Nucleocapsid Protein-RNA Decameric Rings , 2007, Journal of Virology.

[29]  Herren Wu,et al.  Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)* , 2006, Journal of Biological Chemistry.

[30]  G. Lüchters,et al.  Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? , 2004, Virus research.

[31]  N. Simister.  Placental transport of immunoglobulin G. , 2003, Vaccine.

[32]  S. J. Hoffman,et al.  A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease , 2002, The Journal of experimental medicine.

[33]  E. Walsh,et al.  Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. , 1998, The Journal of infectious diseases.

[34]  A. Osterhaus,et al.  A subtype-specific peptide-based enzyme immunoassay for detection of antibodies to the G protein of human respiratory syncytial virus is more sensitive than routine serological tests , 1997, Journal of clinical microbiology.

[35]  W. Britt,et al.  Detection of antibodies to respiratory syncytial virus attachment and nucleocapsid proteins with recombinant baculovirus-expressed antigens , 1997, Journal of clinical microbiology.

[36]  H. Ochs,et al.  The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. , 1988, The Journal of laboratory and clinical medicine.

[37]  W. P. Glezen,et al.  Risk of primary infection and reinfection with respiratory syncytial virus. , 1986, American journal of diseases of children.

[38]  J. Melero,et al.  Influence of respiratory syncytial virus strain differences on pathogenesis and immunity. , 2013, Current topics in microbiology and immunology.

[39]  J. McLellan,et al.  Structure and function of respiratory syncytial virus surface glycoproteins. , 2013, Current topics in microbiology and immunology.

[40]  Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. , 1998, Pediatrics.

[41]  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. , 1998, Pediatrics.

[42]  M. Ogilvie,et al.  Maternal antibody and respiratory syncytial virus infection in infancy , 1981, Journal of medical virology.